133 related articles for article (PubMed ID: 23301519)
1. Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs.
Nasrolahi Shirazi A; Tiwari R; Chhikara BS; Mandal D; Parang K
Mol Pharm; 2013 Feb; 10(2):488-99. PubMed ID: 23301519
[TBL] [Abstract][Full Text] [Related]
2. Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity.
Mozaffari S; Salehi D; Mahdipoor P; Beuttler R; Tiwari R; Aliabadi HM; Parang K
Eur J Med Chem; 2021 Dec; 226():113836. PubMed ID: 34537446
[TBL] [Abstract][Full Text] [Related]
3. [(WR)
Zoghebi K; Aliabadi HM; Tiwari RK; Parang K
Cells; 2022 Jan; 11(2):. PubMed ID: 35053417
[TBL] [Abstract][Full Text] [Related]
4. Hybrid Cyclic-Linear Cell-Penetrating Peptides Containing Alternative Positively Charged and Hydrophobic Residues as Molecular Transporters.
Khayyatnejad Shoushtari S; Zoghebi K; Sajid MI; Tiwari RK; Parang K
Mol Pharm; 2021 Oct; 18(10):3909-3919. PubMed ID: 34491768
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate.
Chhikara BS; Mandal D; Parang K
J Med Chem; 2012 Feb; 55(4):1500-10. PubMed ID: 22276998
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.
Darwish S; Sadeghiani N; Fong S; Mozaffari S; Hamidi P; Withana T; Yang S; Tiwari RK; Parang K
Eur J Med Chem; 2019 Jan; 161():594-606. PubMed ID: 30396106
[TBL] [Abstract][Full Text] [Related]
7. Endosomal pH-activatable poly(ethylene oxide)-graft-doxorubicin prodrugs: synthesis, drug release, and biodistribution in tumor-bearing mice.
Zhou L; Cheng R; Tao H; Ma S; Guo W; Meng F; Liu H; Liu Z; Zhong Z
Biomacromolecules; 2011 May; 12(5):1460-7. PubMed ID: 21332185
[TBL] [Abstract][Full Text] [Related]
8. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
9. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
[TBL] [Abstract][Full Text] [Related]
10. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading.
Chen Z; Zhang P; Cheetham AG; Moon JH; Moxley JW; Lin YA; Cui H
J Control Release; 2014 Oct; 191():123-30. PubMed ID: 24892976
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer.
Saha P; Fortin S; Leblanc V; Parent S; Asselin É; Bérubé G
Steroids; 2012 Sep; 77(11):1113-22. PubMed ID: 22801351
[TBL] [Abstract][Full Text] [Related]
12. Cyclic peptide-capped gold nanoparticles as drug delivery systems.
Nasrolahi Shirazi A; Mandal D; Tiwari RK; Guo L; Lu W; Parang K
Mol Pharm; 2013 Feb; 10(2):500-11. PubMed ID: 22998473
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Evaluation of Homochiral Peptides Containing Arginine and Histidine as Molecular Transporters.
El-Sayed NS; Miyake T; Shirazi AN; Park SE; Clark J; Buchholz S; Parang K; Tiwari R
Molecules; 2018 Jun; 23(7):. PubMed ID: 29966296
[TBL] [Abstract][Full Text] [Related]
14. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells.
Shin DH; Choi KS; Park SA; Cho BS; Lee HS; Ryu JS; Kim TY; Lee CK; Song S; Chung YB
Arch Pharm Res; 2008 Oct; 31(10):1355-61. PubMed ID: 18958428
[TBL] [Abstract][Full Text] [Related]
15. Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.
Andersson L; Davies J; Duncan R; Ferruti P; Ford J; Kneller S; Mendichi R; Pasut G; Schiavon O; Summerford C; Tirk A; Veronese FM; Vincenzi V; Wu G
Biomacromolecules; 2005; 6(2):914-26. PubMed ID: 15762660
[TBL] [Abstract][Full Text] [Related]
16. Protease-Responsive Prodrug with Aggregation-Induced Emission Probe for Controlled Drug Delivery and Drug Release Tracking in Living Cells.
Cheng Y; Huang F; Min X; Gao P; Zhang T; Li X; Liu B; Hong Y; Lou X; Xia F
Anal Chem; 2016 Sep; 88(17):8913-9. PubMed ID: 27503607
[TBL] [Abstract][Full Text] [Related]
17. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
[TBL] [Abstract][Full Text] [Related]
18. Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery.
Scomparin A; Salmaso S; Bersani S; Satchi-Fainaro R; Caliceti P
Eur J Pharm Sci; 2011 Apr; 42(5):547-58. PubMed ID: 21371555
[TBL] [Abstract][Full Text] [Related]
19. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
[TBL] [Abstract][Full Text] [Related]
20. Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin.
Talelli M; Iman M; Varkouhi AK; Rijcken CJ; Schiffelers RM; Etrych T; Ulbrich K; van Nostrum CF; Lammers T; Storm G; Hennink WE
Biomaterials; 2010 Oct; 31(30):7797-804. PubMed ID: 20673684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
